文献速递艾滋病与性传播感染

DORAVIR:法国一项关于接受含多拉韦林抗逆转录病毒方案治疗的HIV-1感染者的全国性调查

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该回顾性全国调查纳入589例接受含多拉韦林方案治疗的HIV-1感染者,其中初治者占8.5%、经治者占91.5%。多拉韦林治疗第3个月和第6个月病毒学控制率分别为88.3%和85.1%。CRF02_AG亚型、更高的血浆HIV-1 RNA峰值、在治疗失败背景下启动多拉韦林及基线V179D突变与病毒学失败相关。

要点

  • 含多拉韦林方案在临床实践中第3个月和第6个月病毒学控制率分别为88.3%和85.1%。
  • CRF02_AG亚型、更高HIV-1 RNA峰值、失败背景下启动多拉韦林及基线V179D突变与病毒学失败相关。
  • 第6个月病毒学失败者中15.9%出现逆转录酶突变,唯一相关因素为基因型敏感评分未完全敏感。

核心结论

  • 本研究是临床实践中描述含多拉韦林方案病毒学疗效并识别病毒学失败或耐药突变出现相关因素的最大规模研究之一,这些因素应在临床管理中加以考虑。

研究设计与样本

  • 法国全国性回顾性调查,纳入初治或经治、接受含多拉韦林抗逆转录病毒方案治疗的HIV-1感染者,共589例。
  • 病毒学失败定义为连续两次血浆病毒载量≥50拷贝/mL或一次病毒载量≥200拷贝/mL。
  • 基因型耐药检测采用Stanford(v9.4.1)和ANRS(v33)算法解读。

主要发现

  • 589例接受含多拉韦林方案治疗的HIV-1感染者中,8.5%为初治,91.5%有既往抗逆转录病毒治疗史;56.9%感染HIV-1 B亚型。
  • 多拉韦林治疗第3个月和第6个月病毒学控制率分别为88.3%和85.1%。
  • 多因素分析显示,CRF02_AG亚型、更高的血浆HIV-1 RNA峰值、在治疗失败背景下启动多拉韦林及基线V179D突变存在与病毒学失败相关。
  • 第6个月发生病毒学失败的88例HIV-1感染者中,15.9%出现HIV逆转录酶突变,中位突变数为2(IQR 1-3)。
  • 多因素分析显示,与突变出现相关的唯一因素为基因型敏感评分未完全敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF. METHODS: A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted. VF was defined as two consecutive plasma viral loads (VLs) of ≥50 copies/mL or one VL of ≥200 copies/mL. Genotypic resistance tests were interpreted using the Stanford (v9.4.1) and ANRS (v33) algorithms. RESULTS: Of the 589 PLWHIV treated with a doravirine-containing regimen, 8.5% were naive and 91.5% had prior antiretroviral experience; 56.9% were infected with HIV-1 B subtype. Overall, 88.3% and 85.1% of participants were virologically controlled at Month (M)3 and M6 of doravirine treatment, respectively. In multivariable analysis, CRF02_AG subtype, higher zenith plasma HIV-1 RNA VL, doravirine initiation in the context of failure and baseline V179D mutation presence were associated with VF. Among 88 PLWHIV who experienced virological failure at M6, 15.9% had a median of 2 (IQR 1-3) HIV RT mutations. In multivariable analysis, the only factor associated with the occurrence of mutations was a genotypic sensitivity score that was not fully sensitive. CONCLUSIONS: This study is one of the largest to characterize the virological efficacy of doravirine-containing regimens in clinical practice and to identify factors associated with VF or emergence of resistance mutations that should be considered in clinical management.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Soulie C, Balde A, Fofana D, et al. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine. J Antimicrob Chemother. 2024. PMID: 38884154. doi:10.1093/jac/dkae194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。